(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 46.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Fennec Pharmaceuticals's revenue in 2025 is $47,538,000.On average, 2 Wall Street analysts forecast FENC's revenue for 2025 to be $1,504,839,226, with the lowest FENC revenue forecast at $1,290,019,874, and the highest FENC revenue forecast at $1,719,658,579. On average, 2 Wall Street analysts forecast FENC's revenue for 2026 to be $2,870,328,712, with the lowest FENC revenue forecast at $2,420,822,322, and the highest FENC revenue forecast at $3,319,835,102.
In 2027, FENC is forecast to generate $4,108,195,911 in revenue, with the lowest revenue forecast at $4,108,195,911 and the highest revenue forecast at $4,108,195,911.